Clinical Trial Update: Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies [Phase 2]

View source ↗

Summary

Phase 2 study evaluating entospletinib in adults with relapsed or refractory hematologic malignancies; study terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Non-follicular Indolent Non-hodgkin Lymphoma

Drugs mentioned

• Entospletinib (entospletinib)

Snippet

Sponsor: Gilead Sciences | Conditions: Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2020-09-23